CARsgen Reports Positive Results for CAR T Therapy in Solid Tumor Cancers
publication date: May 13, 2022
CARsgen, a Shanghai CAR T-cell company, reported positive results in the journal Nature Medicine for its Claudin18.2 CAR T in patients with solid tumor cancers. Interim results from an investigator-led Phase I trial showed the CT041 was effective in patients with advanced gastrointestinal cancers and gastroesophageal junction adenocarcinoma. In 37 patients, the objective response rate was 48.6% with a disease control rate of 73%. CARsgen said that, currently, CT041 is the world's first and only CAR T-cell candidate to start a confirmatory Phase II clinical trial in solid tumor cancers. More details....
Stock Symbol: (HK: 2171)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.